Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAV Regimen in Relapsed/Refractory and Secondary AML
NCT07423104Phase 2Not yet recruiting
- Sponsor
- University of Rochester
- Start
- Dec 2026
- Primary completion
- Feb 2029
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of cladribine in acute myeloid leukemia (AML), sponsored by University of Rochester. Primary endpoint: Composite Complete Remission at 8 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
cladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07423104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07423104.